A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (MORPHEUS-LIVER)
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Sponsor: Adagene Inc
A observational or N/A phase clinical study on Advanced Liver Cancers, this trial is actively recruiting participants. The trial is conducted by Adagene Inc and has accumulated 59 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
59 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Phase: PHASE1/PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 54 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Contact Information
- Adagene Inc
- Hoffmann-La Roche
- Immune-Onc Therapeutics
- NiKang Therapeutics, Inc.
- Tempest Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .